Correction: Lupus community panel proposals for optimising clinical trials: 2018 (Lupus Science and Medicine (2018) 5 (e000258) DOI: 10.1136/lupus-2018-000258);Lupus community panel proposals for optimising clinical trials: 2018

Lupus Science and Medicine

Volumn 5, Issue 1, 2018, Pages

  Merrill, Joan T ^a   Manzi, Susan ^b   Aranow, Cynthia ^c   Askenase, Anca ^d   Bruce, Ian ^e   Chakravarty, Eliza ^a   Chong, Ben ^f   Costenbader, Karen ^g   Dall'Era, Maria ^h   Ginzler, Ellen ⁱ   Hanrahan, Leslie ^j   Kalunian, Ken ^k   Merola, Joseph ^g   Raymond, Sandra ^j   Rovin, Brad ^l   Saxena, Amit ^m   Werth, Victoria P ⁿ  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b ALLEGHENY HEALTH NETWORK   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Downstate Health Sciences University   (United States)

^j Lupus Foundation of America Inc   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^m NEW YORK UNIVERSITY   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

clinical trials; outcome measures; trial design

Indexed keywords

ANTIBODY SPECIFICITY; ARTICLE; BRITISH ISLES LUPUS ASSESSMENT GROUP 2004 INDEX; DISEASE ACTIVITY; DISEASE ASSESSMENT; HUMAN; IMMUNOMODULATION; PATIENT CARE; POLYPHARMACY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SLEDAI; STUDY DESIGN; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS RESPONDER INDEX;

EID: 85048137635     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2018-000258corr1     Document Type: Erratum

References (136)

1. ClinicalTrials.gov. 740 Studies found for: lupus. https://www.clinicaltrials.gov/ct2/results?term=lupus&pg=3
2. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
3. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
4. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 2017;69:1016-27.
5. ClinicalTrials.gov. 102 Studies found for: Phase 3 | Lupus. https://clinicaltrials.gov/ct2/results?term=Phase+3&cond=Lupus&draw=9&pg=1
6. Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2015;74:2006-15.
7. Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis 2015;74:1667-75.
8. Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379-89.
9. Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:332-40.
10. Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:323-31.
11. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183-90.
12. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376-86.
13. Dooley MA, Pendergraft W, Ginzler EM, et al. 2016. Speed of remission with the use of voclosporin, mmf and low dose steroids: results of a global lupus nephritis study 2016. ACR/ARHP Annual Meeting. Abstract Number 5L.
14. Clowse ME, Wallace DJ, Furie RA, et al. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. Arthritis Rheumatol 2017;69:362-75.
15. Merrill JT, Martin RS, Shanahan WR, et al. Phase 3 trial results with Blisibimod, a selective inhibitor of B-cell Activating Factor in subjects with SLE. EULAR 2017. Abstract number SAT0240.
16. Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016;75:196-202.
17. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
18. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
19. Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80.
20. Kalunian KC, Davis JC, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8.
21. Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an antiinterferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebocontrolled study. Ann Rheum Dis 2016;75:1909-16.
22. Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013;65:2368-79.
23. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:3077-87.
24. Dai C, Deng Y, Quinlan A, et al. Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol 2014;31:87-96.
25. Marion TN, Postlethwaite AE. Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus. Semin Immunopathol 2014;36:495-517.
26. Mirabelli G, Cannarile F, Bruni C, et al. One year in review 2015: systemic lupus erythematosus. Clin Exp Rheumatol 2015;33:414-25.
27. Yee CS, Su L, Toescu V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology 2015;54:836-43.
28. Björk M, Dahlström Ö, Wetterö J, et al. Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskelet Disord 2015;16:188.
29. Hanly JG, Su L, Urowitz MB, et al. Mood disorders in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Rheumatol 2015;67:1837-47.
30. Bruce IN, O'Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2015;74:1706-13.
31. Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med 2015;2:e000066.
32. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006;33:1570-7.
33. Baker K, Pope J, Fortin P, et al. Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. Lupus 2009;18:1281-8.
34. Pego-Reigosa JM, Rúa-Figueroa Í, López-Longo FJ, et al. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. Lupus 2015;24:720-9.
35. Danoff-Burg S, Friedberg F. Unmet needs of patients with systemic lupus erythematosus. Behav Med 2009;35:5-13.
36. Croyle L, Morand EF. Optimizing the use of existing therapies in lupus. Int J Rheum Dis 2015;18:129-37.
37. http://www.lupus.org/pages/unveil/survey
38. Lerstrom K, Crimmings M, Govoni M, et al. Disease symptoms, treatment satisfaction, and coping strategies in patients with lupus. Poster session presented at: EULAR conference. London, UK;May 25-28, 2011;
39. Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8.
40. Vera-Recabarren MA, García-Carrasco M, Ramos-Casals M, et al. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. Br J Dermatol 2010;162:91-101.
41. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
42. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
43. Aberle T, Bourn RL, Chen H, et al. Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. Lupus Sci Med 2017;4:e000176.
44. Wu H, Zeng J, Yin J, et al. Organ-specific biomarkers in lupus. Autoimmun Rev 2017;16:391-7.
45. Romick-Rosendale LE, Brunner HI, Bennett MR, et al. Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. Arthritis Res Ther 2011;13:R199.
46. Der E, Ranabothu S, Suryawanshi H, et al. Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight 2017;2:211.
47. Merrill JT. Connective tissue diseases: Is SLE many single-organ diseases or an overlapping spectrum? Nat Rev Rheumatol 2015;11:385-6.
48. Skiljevic D, Bonaci-Nikolic B, Brasanac D, et al. Apoptosis of keratinocytes and serum DNase I activity in patients with cutaneous lupus erythematosus: relationship with clinical and immunoserological parameters. J Eur Acad Dermatol Venereol 2017;31:523-9.
49. Goel N. Welcome to IQVIA. http://www.quintiles.com/blog/lupustrials-are-on-the-rise
50. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006;15:308-18.
51. Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-68.
52. Ferucci ED, Johnston JM, Gaddy JR, et al. Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009. Arthritis Rheumatol 2014;66:2494-502.
53. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008;112:228-42.
54. U S Food and Drug Administration. Guidance for Industry Systemic Lupus Erythematosus - Developing Medical Products for Treatment. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf
55. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78.
56. Ritterhouse LL, Crowe SR, Niewold TB, et al. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum 2011;63:3931-41.
57. Symonds RP, Lord K, Mitchell AJ, et al. Recruitment of ethnic minorities into cancer clinical trials: experience from the front lines. Br J Cancer 2012;107:1017-21.
58. Roberson NL. Clinical trial participation. Viewpoints from racial/ethnic groups. Cancer 1994;74:2687-91.
59. Research!America. National Poll on Clinical Research conducted in partnership with Zogby Analytics, 2013.
60. Joseph G, Dohan D. Recruiting minorities where they receive care: Institutional barriers to cancer clinical trials recruitment in a safetynet hospital. Contemp Clin Trials 2009;30:552-9.
61. McCaskill-Stevens W, Pinto H, Marcus AC, et al. Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association. J Clin Oncol 1999;17:1029-39.
62. Freimuth VS, Quinn SC, Thomas SB, et al. African Americans' views on research and the Tuskegee Syphilis Study. Soc Sci Med 2001;52:797-808.
63. Siminoff LA, Zhang A, Colabianchi N, et al. Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol 2000;18:1203-11.
64. Morgan SE, Occa A, Potter J, et al. "You Need to Be a Good Listener": Recruiters' Use of Relational Communication Behaviors to Enhance Clinical Trial and Research Study Accrual. J Health Commun 2017;22:95-101.
65. Larkey LK, Staten LK, Ritenbaugh C, et al. Recruitment of Hispanic women to the Women's Health Initiative. the case of Embajadoras in Arizona. Control Clin Trials 2002;23:289-98.
66. Howerton MW, Gibbons MC, Baffi CR, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer 2007;109:465-76.
67. Hudson SV, Momperousse D, Leventhal H. Physician perspectives on cancer clinical trials and barriers to minority recruitment. Cancer Control 2005;12(Suppl 2):93-6.
68. Thanou A, Merrill JT. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nat Rev Rheumatol 2014;10:23-34.
69. Thanou A, Chakravarty E, James JA, et al. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Rheumatology 2014;53:2175-81.
70. Thanou A, Chakravarty E, James JA, et al. Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Sci Med 2014;1:e000005.
71. Petri M, Perez-Gutthann S, Longenecker JC, et al. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991;91:345-53.
72. Durcan L, Clarke WA, Magder LS, et al. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 2015;42:2092-7.
73. Mehat P, Atiquzzaman M, Esdaile JM, et al. Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res 2017;69:1706-13.
74. Merrill JT, Wallace DL, Wax S, et al, 2016. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24-week randomized, placebo-controlled, phase iib study. ACR/ARHP Annual Meeting. Abstract number 12L.
75. Wallace DJ, Strand V, Merrill JT, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis 2017;76:534-42.
76. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9.
77. Merrill JT, Immermann F, Whitley M, et al. The Biomarkers of Lupus Disease Study: a bold approach may mitigate interference of background immunosuppressants in clinical trials. Arthritis Rheumatol 2017;69:1257-66.
78. University of Maryland Medical Center. Systemic lupus erythematosus. http://umm.edu/health/medical/reports/articles/systemic-lupus-erythematosus
79. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74.
80. Buyon JP, Cohen P, Merrill JT, et al. A highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Sci Med 2015;2:e000087.
81. Hoffman RW, Merrill JT, Alarcón-Riquelme MM, et al. Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Arthritis Rheumatol 2017;69:643-54.
82. Bandyopadhyay S, Connolly SE, Jabado O, et al; De-Convolution of Whole Blood Transcriptomic Data from a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus, 2015.ACR/ARHP Annual Meeting. Abstract number 2067.
83. Lu P, Fleischmann R, Curtis C, et al. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Lupus 2018;27:290-302.
84. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-37.
85. Touma Z, Gladman DD, Ibañez D, et al. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol 2011;38:275-84.
86. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med Overseas Ed 2005;353:2550-8.
87. Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007;56:4113-9.
88. Bruce IN, Gordon C, Merrill JT, et al. Clinical trials in lupus: what have we learned so far? Rheumatology 2010;49:1025-7.
89. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
90. Anders HJ, Jayne DR, Rovin BH. Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nat Rev Nephrol 2016;12:205-16.
91. Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015;67:1305-13.
92. Corapi KM, Dooley MA, Pendergraft WF. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther 2015;17:110.
93. Iaccarino L, Bettio S, Reggia R, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res 2017;69:115-23.
94. Fleischmann R, Goldman JA, Leirisalo-Repo M, et al. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Curr Med Res Opin 2014;30:2139-49.
95. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
96. Pincus T, Maclean R, Yazici Y, et al. Quantitative measurement of patient status in the regular care of patients with rheumatic diseases over 25 years as a continuous quality improvement activity, rather than traditional research. Clin Exp Rheumatol 2007;25(6 Suppl 47):69-81.
97. Witt M, Grunke M, Proft F, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 2013;22:1142-9.
98. Askanase A, Shum K, Mitnick H. Systemic lupus erythematosus: an overview. Soc Work Health Care 2012;51:576-86.
99. Tani C, Chiara T, D'Aniello D. et al. MRI pattern of arthritis in systemic lupus erythematosus: a comparative study with rheumatoid arthritis and healthy subjects. Skeletal Radiol 2015;44:267-6.
100. Lins CF, Santiago MB. Ultrasound evaluation of joints in systemic lupus erythematosus: a systematic review. Eur Radiol 2015;25:2688-92.
101. Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol 2009;145:255-60.
102. Chang AY, Piette EW, Foering KP, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011;147:1261-7.
103. Ikeda T, Kanazawa N, Furukawa F. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. J Dermatol 2012;39:531-5.
104. Yokogawa N, Tanikawa A, Amagai M, et al. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol 2013;23:249-55.
105. Liang MH, Socher SA, Larson MG, et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
106. Parodi A, Massone C, Cacciapuoti M, et al. Measuring the activity of the disease in patients with cutaneous lupus erythematosus. Br J Dermatol 2000;142:457-60.
107. Faust HB, Gonin R, Chuang TY, et al. Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol 1997;133:1443-8.
108. Albrecht J, Werth VP. Outcome measures in cutaneous autoimmune disease: dermatomyositis and lupus erythematosus In: The skin in systemic autoimmune disease: Elsevier, 2006.
109. Albrecht J, Werth VP. Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther 2007;20:93-101.
110. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889-94.
111. Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008;144:173-80.
112. Krathen MS, Dunham J, Gaines E, et al. The cutaneous lupus erythematosus disease activity and severity index: expansion for rheumatology and dermatology. Arthritis Rheum 2008;59:338-44.
113. Jolly M, Kazmi N, Mikolaitis RA, et al. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physicianand patient-assessed health outcome measures. J Am Acad Dermatol 2013;68:618-23.
114. Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011;147:203-8.
115. Chang AY, Ghazi E, Okawa J, et al. Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. JAMA Dermatol 2013;149:104-6.
116. Vashisht P, Borghoff K, O'Dell JR, et al. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus 2017;26:857-64.
117. Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 2012;166:616-23.
118. Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, et al. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012;14:R265.
119. De Souza A, Strober BE, Merola JF, et al. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol 2012;11:1224-6.
120. Werth VP, Hough DR, Korish S, et al. A phase 2, randomized, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, and tolerability of CC220 in subjects with systemic lupus erythematosus. Lupus Sci Med 2016;3(Suppl 1):A41.
121. Ky C, Swasdibutra B, Khademi S, et al. Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept Study. Dermatol Reports 2015;7:5804.
122. Braunstein I, Klein R, Okawa J, et al. The IFN-regulated gene signature is elevated in SCLE and DLE and correlates with CLASI score. Br J Dermatol 2012;166:971-5.
123. Oh SH, Roh HJ, Kwon JE, et al. Expression of interleukin-17 is correlated with interferon-α expression in cutaneous lesions of lupus erythematosus. Clin Exp Dermatol 2011;36:512-20.
124. Verma SM, Okawa J, Propert KJ, et al. The impact of skin damage due to cutaneous lupus on quality of life. Br J Dermatol 2014;170:315-21.
125. Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011;64:849-58.
126. Zhao CY, Hao EY, Oh DD, et al. A comparison study of clinicianrated atopic dermatitis outcome measures for intermediate- to dark-skinned patients. Br J Dermatol 2017;176:985-92.
127. Petri M, Merrill JT, Davis JC, et al. Validation of the revised selena flare index in systemic Lupus Erythematosus. America College of Rheumatology Annual Meeting. 2012. abstract number 2542.
128. Ruperto N, Hanrahan LM, Alarcón GS, et al. International consensus for a definition of disease flare in lupus. Lupus 2011;20:453-62.
129. Holloway L, Humphrey L, Heron L, et al. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance. Health Qual Life Outcomes 2014;12:116.
130. Annapureddy N, Devilliers H, Jolly M. Patient-reported outcomes in lupus clinical trials with biologics. Lupus 2016;25:1111-21.
131. Leong KP, Kong KO, Thong BY, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 2005;44:1267-76.
132. Jolly M, Pickard AS, Block JA, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 2012;42:56-65.
133. Meacock R, Harrison M, McElhone K, et al. Mapping the diseasespecific LupusQoL to the SF-6D. Qual Life Res 2015;24:1749-58.
134. Jolly M, Cornejo J, Mikolaitis RA, et al. LupusPRO and responsiveness the changes in health status and disease activity over time. Arthritis Rheum 2011;63:S898.
135. Giangreco D, Devilliers H, Annapureddy N, et al. LupusPRO is Responsive to Changes in Disease Activity Over Time. Paris: EULAR, 2014.
136. Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014;73:838-44.